We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Irrigated Ablation System Evaluation for Atrial Fibrillation (AF) (IRASE-AF)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01056328
First Posted: January 26, 2010
Last Update Posted: May 23, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
St. Jude Medical
Results First Submitted: January 28, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Single (Participant);   Primary Purpose: Treatment
Condition: Paroxysmal Atrial Fibrillation
Interventions: Device: SJM Irrigated Cardiac Ablation System
Device: FDA approved Open Irrigated RF Ablation System

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
SJM Cardiac Ablation System SJM Irrigated Cardiac Ablation System: Irrigated ablation catheter
FDA Approved Open Irriagated RF Ablation System FDA approved Open Irrigated RF Ablation System: Irrigated ablation catheter

Participant Flow:   Overall Study
    SJM Cardiac Ablation System   FDA Approved Open Irriagated RF Ablation System
STARTED   164   160 
COMPLETED   147   144 
NOT COMPLETED   17   16 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
SJM Cardiac Ablation System SJM Irrigated Cardiac Ablation System: Irrigated ablation catheter
FDA Approved Open Irriagated RF Ablation System FDA approved Open Irrigated RF Ablation System: Irrigated ablation catheter
Total Total of all reporting groups

Baseline Measures
   SJM Cardiac Ablation System   FDA Approved Open Irriagated RF Ablation System   Total 
Overall Participants Analyzed 
[Units: Participants]
 164   160   324 
Age 
[Units: Years]
Mean (Standard Deviation)
 58.5  (12.4)   60.6  (9.7)   59.5  (11.2) 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   96   96   192 
>=65 years   68   64   132 
Gender 
[Units: Participants]
     
Female   59   66   125 
Male   105   94   199 
Region of Enrollment 
[Units: Participants]
     
United States   149   149   298 
Korea, Republic of   9   7   16 
Canada   6   4   10 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Confirmation of Entrance Block in the Pulmonary Veins   [ Time Frame: 20 minutes after initial isolation ]

2.  Primary:   Incidence of Adverse Events Included in the Pre-specified Composite   [ Time Frame: 7 days ]

3.  Primary:   Incidence of Adverse Events Included in the Pre-specified Composite.   [ Time Frame: 12 months ]

4.  Secondary:   Documented (> 30 Seconds) Asymptomatic Episodes of Atrial Fibrillation (AF), Atrial Flutter (AFL), or Atrial Tachicardia (AT) After the Blanking Period   [ Time Frame: 12 months ]

5.  Secondary:   Early Onset (Within 90 Days) of SAE/Non-serious AEs and Late Onset (After 90 Days) SAEs   [ Time Frame: 12 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Nicole Glowacki, Clinical Project Manager
Organization: St. Jude Medical
phone: 651-756-3432
e-mail: NGlowacki@sjm.com



Responsible Party: St. Jude Medical
ClinicalTrials.gov Identifier: NCT01056328     History of Changes
Other Study ID Numbers: 90030928
First Submitted: January 22, 2010
First Posted: January 26, 2010
Results First Submitted: January 28, 2014
Results First Posted: May 23, 2014
Last Update Posted: May 23, 2014